Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis
- 10 January 2008
- journal article
- Published by Elsevier BV in Chemico-Biological Interactions
- Vol. 171 (1), 26-36
- https://doi.org/10.1016/j.cbi.2007.09.004
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Control of Copper Status for Cancer TherapyCurrent Cancer Drug Targets, 2005
- Nanoparticle and other metal chelation therapeutics in Alzheimer diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005
- Copper Chelation Delays the Onset of Prion DiseasePublished by Elsevier BV ,2003
- Cell death in human acute myelogenous leukemic cells induced by pyrrolidinedithiocarbamateApoptosis, 2003
- Transition metal chelator therapy - a potential treatment for Alzheimer's disease?Frontiers in Bioscience-Landmark, 2002
- The Role of Copper Suppression as an Antiangiogenic Strategy in Head and Neck Squamous Cell CarcinomaThe Laryngoscope, 2001
- Pyrrolidine dithiocarbamate inhibits serum-induced NF-κB activation and induces apoptosis in ROS 17/2.8 osteoblastsInternational Immunopharmacology, 2001
- Pyrrolidinedithiocarbamate increases the therapeutic index of 5-fluorouracil in a mouse modelGastroenterology, 2000
- Dithiocarbamate Toxicity toward Thymocytes Involves Their Copper-Catalyzed Conversion to Thiuram Disulfides, Which Oxidize Glutathione in a Redox Cycle without the Release of Reactive Oxygen SpeciesArchives of Biochemistry and Biophysics, 1998
- Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAF1/CIP1 via C/EBPβNature Medicine, 1997